Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
08:30am, Friday, 01'st Sep 2023
CVS Health is getting into the biosimilar drug business that Viatris just exited. CVS could potentially target other types of generic medicines next.
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
03:49pm, Thursday, 31'st Aug 2023
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Viatris Stock: Bear vs. Bull
08:45am, Thursday, 31'st Aug 2023
Viatris is trying to launch generic versions of Novo Nordisk's Ozempic and Wegovy. It should experience an uptick in growth soon, and the stock's valuation is cheap.
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross
11:16am, Wednesday, 30'th Aug 2023
From a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just reached a key level of support. VTRS's 50-day simple moving average crossed above its 200-day simple m
Dividend Stock Watch List: Lanny's September 2023 Edition
06:56am, Monday, 28'th Aug 2023
The stock market, specifically the S&P 500, is still lurking over 4,400, up 16% this year. UPS is projecting to earn between $85 billion to $100 billion in revenue, just large amounts, even during a t
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
05:00pm, Thursday, 24'th Aug 2023
One of these high-yield pharma stocks stands out as a better buy right now.
Where Will Viatris Be in 5 Years?
07:45am, Friday, 18'th Aug 2023
Viatris' near-term focus now is to reduce its heavy debt load. The company is also simplifying its business through more divestitures.
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
11:06am, Wednesday, 16'th Aug 2023
Viatris is trying to get its two generic versions of semaglutide approved for sale. Novo Nordisk is suing Viatris to prevent the approval from happening.
Viatris: Turning Point For Cheap Pharma Stock
04:04am, Friday, 11'th Aug 2023
Viatris reported strong second-quarter earnings, beating estimates on both revenue and earnings per share. The company showed signs of sales growth on a divestiture adjusted basis and is on track for
Is Viatris Stock Good for Dividend Income?
09:37am, Wednesday, 09'th Aug 2023
Viatris is paying down its debt and planning to return capital to shareholders too. The generic drugmaker's growth hasn't been very impressive so far.
Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say
10:39pm, Monday, 07'th Aug 2023
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to
S&P 500 Gains and Losses Today: Stocks Take Off After Earnings Reports
05:45pm, Monday, 07'th Aug 2023
The S&P 500 snapped a four-day losing streak on Monday, Aug. 7, 2023, rising 0.9% after the latest round of earnings reports.
Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug
03:50pm, Monday, 07'th Aug 2023
Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its n
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
01:38pm, Monday, 07'th Aug 2023
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
Markets Mixed at Midday on New Earnings Reports, Upcoming Data
01:10pm, Monday, 07'th Aug 2023
U.S. equities were mixed at midday on Monday, Aug. 7, 2023, after the latest earnings reports and ahead of key inflation data due later in the week.
